Table 3. The plasma of 5-Fluorouracil (5-FU) (100 mg/kg, i.v.) pharmacokinetics in rats treated with and without MMP-8 inhibitor then delivered to whole pelvic irradiation with 2 Gy.
| Parameters | Controls(withoutsolvent) | Controls (withsolvent) | Whole pelvicIrradiation 2 Gy | |
| with solvent | with solvent and MMP-8 inhibitor | |||
| 5-FU | ||||
| AUC (min µg/mL) | 4285±215* | 4285±141* | 3305±28 | 3963±427* |
| t1/2 (min) | 33.3±16.1 | 27.8±3.0 | 31.0±8.8 | 32.3±9.9 |
| Cmax (µg/mL) | 151±17 | 146±35 | 132±51 | 122±29 |
| MRT (min) | 37±1.7* | 36±3.7* | 26±3.8 | 36±2.1* |
| CL (mL/kg/min) | 23.4±1.1* | 23.4±0.8* | 30.3±0.3 | 25.4±2.8* |
| Vss (mL/kg) | 859±22 | 836±97 | 784±110 | 911±127 |
AUC: area under the plasma concentration vs. time curve; t1/2: terminal elimination phase half-life; Cmax: maximum observed plasma concentration; MRT: mean residence time; CL: total plasma clearance; Vss: volume of distribution at steady state.
*The mean difference is significant at the 0.05 level in comparison to the whole pelvic irradiation with solvent and 5-FU group.